Join to View Full Profile
10833 LeConte Ave, 66-128 CHSLos Angeles, CA 90095
Phone+1 310-206-2436
Fax+1 310-206-2436
Dr. Pantuck is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Rutgers Health/Robert Wood Johnson Medical SchoolResidency, Urology, 1995 - 1999
Rutgers Health/Robert Wood Johnson Medical SchoolResidency, Surgery, 1993 - 1995
Rutgers Robert Wood Johnson Medical SchoolClass of 1993
Certifications & Licensure
CA State Medical License 1999 - 2027
FL State Medical License 2017 - 2019
NJ State Medical License 1995 - 1999
American Board of Urology Urology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017
- Fellow (FACS) American College of Surgeons
Clinical Trials
- Biological Therapy in Treating Patients With Prostate Cancer Start of enrollment: 2002 Mar 01
- Pomegranate Juice in Treating Patients With Recurrent Prostate Cancer Start of enrollment: 2004 Nov 30
- Docetaxel and Erlotinib in Treating Older Patients With Prostate Cancer Start of enrollment: 2004 May 01
Publications & Presentations
PubMed
- First, Do No Harm.Dimitrios Stefanoudakis, Allan J Pantuck, Alexandra Drakaki
Journal of the National Comprehensive Cancer Network. 2026-03-01 - Frontiers in Systemic Therapy for Unresectable or Metastatic Adrenocortical Carcinoma: Harnessing Novel Therapeutic Approaches.Adam E Singer, Nikhita Kathuria-Prakash, David Shabsovich, Lizette Garcia, Leland Damron
Clinical Medicine Insights. Oncology. 2025-01-01 - 55 citations[Zr]Zr-girentuximab for PET-CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trial.Brian Shuch, Allan J Pantuck, Jean-Christophe Bernhard, Michael A Morris, Viraj Master
The Lancet. Oncology. 2024-10-01
Other
- Surveillance for metastatic disease after nephrectomy for renal cell carcinomaPantuck AJ, Shuch B, Klatte T
http://www.uptodate.com/contents/surveillance-for-metastatic-disease-after-nephrectomy-for-renal-cel
UpToDate, Wolters Kluwer Health - 2012-08-16
Authored Content
- Re: Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma After NephrectomyFebruary 2018
- Re: Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma After NephrectomyFebruary 2018
Press Mentions
New Imaging Technique Accurately Detects Aggressive Kidney Cancer, Claims StudyOctober 21st, 2024- Athos Therapeutics Receives Regulatory Approval to Commence Phase I Clinical Trial of ATH-063March 29th, 2023
- Abraham Verghese MD, Noted Stanford Physician and Recipient of the National Humanities Medal at the White House from Former President Obama, Appointed to the Board of Directors of Athos TherapeuticsMay 18th, 2022
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
